Q-omics provides the consensus-scored LINC02585 profile across patient tissues and cancer cell-line models. LINC02585 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC02585 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, LINC02585 RNA expression shows 16,209 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, LIHC, and ACC as cancer lineages where LINC02585 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02585 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02585 survival associations across molecular data types. LINC02585 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02585 RNA expression–survival associations across cancer types. High LINC02585 expression shows unfavorable associations in UCEC, KIRC, ACC and LIHC, but favorable associations in OV and SKCM. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for LINC02585 RNA expression.
This table summarizes LINC02585 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02585. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02585 shows higher tumor expression in LIHC, COAD, LUAD, STAD, KIRP and HNSC. The LIHC box plot shows higher LINC02585 RNA expression in tumor versus normal tissue (log2 FC = +1.496, t-test p < 0.001).
This table shows molecular features associated with LINC02585 in patient tissues and cancer cell lines. In patient samples, LINC02585 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC02585 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
